Kjellstrand Carl M, Buoncristiani Umberto, Ting George, Traeger Jules, Piccoli Giordina B, Sibai-Galland Roula, Young Bessie Ann, Blagg Christopher R
Loyola University, Chicago, IL, USA.
Nephrol Dial Transplant. 2008 Oct;23(10):3283-9. doi: 10.1093/ndt/gfn210. Epub 2008 May 5.
Survival statistics for daily haemodialysis are lacking as most centres providing this have treated only a small number of patients for short observation times. We pooled our 23-year, 1006-patient-year, five-centre experience of 415 patients treated by short daily haemodialysis.
One hundred and fifty patients were treated in-centre, most because of medical complications and 265 by home or self-care haemodialysis. Patients were on daily haemodialysis for 29 +/- 31 (0-272) months. Forty-two percent had primary and 31% had secondary renal failure. Treatment time was 136 +/- 35 min, frequency 5.8 +/- 0.5 times/week and weekly stdKt/V 2.7 +/- 0.55.
Eighty-five patients (20%) died; 5-year cumulative survival was 68 +/- 4.1% and 10-year survival was 42 +/- 9%. Age, secondary renal failure and in-centre dialysis were associated with mortality, while gender, frequency of dialysis (5, 6 or 7 per week), continent, country and blood access were not. Survival was compared with matched patients from the USRDS 2005 Data Report using the standardized mortality ratio and cumulative survival curves. Both comparisons showed that the survival of the daily haemodialysis patients was 2-3 times higher and the predicted 50% survival time 2.3-10.9 years longer than that of the matched US haemodialysis patients. Survival of patients dialyzing daily at home was similar to that of age-matched recipients of deceased donor renal transplants.
Survival of patients on short daily haemodialysis was 2-3 times better than that of matched three times weekly haemodialysis patients reported by the USRDS.
由于大多数提供每日血液透析的中心仅治疗了少数患者且观察时间较短,因此缺乏每日血液透析的生存统计数据。我们汇总了我们在23年里、涉及1006患者年、五个中心对415例接受短程每日血液透析治疗患者的经验。
150例患者在中心接受治疗,大多数是由于医疗并发症,265例通过家庭或自我护理血液透析治疗。患者接受每日血液透析29±31(0 - 272)个月。42%为原发性肾衰竭,31%为继发性肾衰竭。治疗时间为136±35分钟,频率为5.8±0.5次/周,每周标准Kt/V为2.7±0.55。
85例患者(20%)死亡;5年累积生存率为68±4.1%,10年生存率为42±9%。年龄、继发性肾衰竭和中心透析与死亡率相关,而性别、透析频率(每周5、6或7次)、大洲、国家和血管通路则无关。使用标准化死亡率比和累积生存曲线将生存率与来自美国肾脏数据系统(USRDS)2005年数据报告中匹配的患者进行比较。两项比较均显示,每日血液透析患者的生存率比匹配的美国血液透析患者高2至3倍,预计50%生存率的时间长2.3至10.9年。在家中进行每日透析的患者生存率与年龄匹配的已故供体肾移植受者相似。
短程每日血液透析患者的生存率比USRDS报告的匹配的每周三次血液透析患者高2至3倍。